Feedback / Questions
ENS-002 - Concerto Biosci
https://www.prnewswire.com/news-releases/concerto-biosciences-announces-first-participant-dosed-with-live-biotherapeutic-ens-002-in-phase-1-trial-for-atopic-dermatitis-302310102.html
Nov 19, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next